Aldoxorubicin demonstrated response rates that culminated in a higher incidence of stable disease versus doxorubicin as a first-line treatment for advanced soft tissue sarcomas, according to results from an ongoing phase IIb study.
Novel Agents Under Investigation for the Treatment of GIST
Seth A. Wander, MD, PhD; Kara M. Schenk, MD
Patrick I. Borgen, MD; Joshua Feinberg, MD; Gary Schwartz, MD, FASA
Marla D. Lipsyc-Sharf, MD; Yan Ji, MD
Marla D. Lipsyc-Sharf, MD; Kimberly Ku, MD
Patrick I. Borgen, MD; Reshma Jagsi, MD, DPhil; Hope S. Rugo, MD, FASCO
Patrick I. Borgen, MD; E. Shelley Hwang, MD, MPH; Mark E. Robson, MD
Heather McArthur, MD, MPH; Komal Jhaveri, MD, FACP; Sara Tolaney, MD, MPH; Seth A. Wander, MD, PhD
Rita Nanda, MD; William Gradishar, MD, FASCO, FACP; Komal Jhaveri, MD, FACP; Kevin Kalinsky, MD, MS
Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC
Hope S. Rugo, MD, FASCO; Sara Hurvitz, MD, FACP; Jennifer Litton, MD, MHCM; Heather McArthur, MD, MPH
Joyce O’Shaughnessy, MD; William Gradishar, MD, FASCO, FACP; Heather McArthur, MD, MPH; Eleni Anastasia Tousimis, MD, MBA, FACS
May 22, 2026
Reshma Jagsi, MD, DPhil; Kevin Kalinsky, MD, MS; Hope S. Rugo, MD, FASCO; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS
William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD
Aditya Bardia, MD, MPH, FASCO; Joyce O’Shaughnessy, MD; Hope S. Rugo, MD; Paolo Tarantino, MD
Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO
Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc
Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD
Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO
Filipa Lynce, MD; Rita Nanda, MD
Joyce O’Shaughnessy, MD
Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO
Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO
Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD
